Efrat Luttwak
@Efrat_Luttwak
Followers
69
Following
325
Statuses
95
RT @BloodJournal: The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy…
0
28
0
RT @MSKCME: Registration is now open for the 9th Annual #MSKlymphomaCME. Discover the latest breakthroughs in #lymphoma, from advancements…
0
6
0
RT @UrviShahMD: Our study on dietary risk factors for MGUS made the list of the 2024 @BloodAdvances most read articles @JanineMJoseph htt…
0
10
0
Cycle for Survival has a special year-end match going on — every donation is being doubled! It’s an amazing opportunity to make an even bigger impact. If you’re able to donate, even a small amount, it would mean so much. Here’s the link to donate:
0
0
0
RT @DrJFriedberg: The safety and high activity of N-AVD will lead to a new standard of care for most older patients with Hodgkin lymphoma i…
0
10
0
RT @arivasdelgado: Best way to kick off the day at #ASH24? A morning run with great friends! 🏃🏻♂️ Let’s go! 💪 #ASHRun
0
1
0
Today is #GivingTuesday- we can take part in to maximize our impact on lymphoma cancer research and help reach our fundraising goal. (They match the donation!) - Team Page: #msk #lymphoma #cycle for survival
0
0
1
RT @mike_dickinson1: The current landscape of frontline large B-cell lymphoma trials | Blood | highly recommended reading. #lymsm https:…
0
23
0
RT @graham74GC: Real shame that zandelisib - a PI3K delta inhibitor - has had development terminated. The ph II TIDAL study showed good eff…
0
1
0
RT @lymphomahub: CONGRESS | #SOHO2024
@gilles_salles @MSKCancerCenter discusses how to sequence therapies in R/R DLBCL, with the aim to opt…
0
27
0
RT @CwynKate: How I Treat acute venous thromboembolism in patients with brain tumors @BloodJournal
0
7
0
RT @DrMvandenBrink: FDA Approves CAR T Cell Treatment for Resistant Mantle Cell Lymphoma | Memorial Sloan Kettering Cancer Center https://t…
0
4
0
RT @MSKCancerCenter: A recent study led by investigators at MSK included a comprehensive analysis of non relapse mortality after #CARTcellt…
0
8
0
RT @MediHumdani: CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma #lymsm @priyankapophali @joshuaafein @mshadman…
0
22
0
RT @KRejeski: 🚨 hot off the press 🚨 A (perhaps) underestimated aspect of CAR T-cell therapy: non-relapse mortality. Check out our new me…
0
55
0
RT @SantoshVardhana: It’s my pleasure to share a preprint describing @falchi_lorenzo and @VardhanaLab explorations into how bispecific anti…
0
13
0
RT @PaolaGhione_MD: Our thoughts on Pola in DLBCL with @gilles_salles are out! Check it out on @Haematologica @MSKCancerCenter @MSK_DeptOfM…
0
9
0